Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

NCT07680946 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Ublituximab

Sponsor

TG Therapeutics, Inc.